Read by QxMD icon Read

microRNA antiplatelet

Yueh-Chung Chen, Feng-Yen Lin, Yi-Wen Lin, Shu-Meng Cheng, Chao-Chien Chang, Rong-Ho Lin, Chun-Ling Chuang, Jehn-Shing Sheu, Shan-Min Chen, Chien-Sung Tsai
PURPOSE: The expression level of platelet microRNAs (miRNAs) correlates with heart disease and may be altered by antiplatelet therapy. This study aims to assess whether certain miRNAs are associated with treatment response by platelets in patients who received percutaneous coronary intervention and antiplatelet therapy. The dynamic expression of certain miRNAs in patients receiving different antiplatelet regimens was also investigated. METHODS: Healthy subjects (N = 20) received no-stent or antiplatelet therapy (as control), and patients (N = 155) who underwent stent implant and received treatment regimens that included aspirin plus clopidogrel, ticagrelor, or cilostazol were included...
February 19, 2019: Cardiovascular Drugs and Therapy
Helle Glud Binderup, Kim Houlind, Claus Lohman Brasen, Jonna Skov Madsen
OBJECTIVE: Aspirin is a widely used platelet inhibitor to prevent thrombotic events. However, in 25% of patients the antiplatelet effect is insufficient. The current study aimed to validate a newly developed PDW-miR92a-score as a biomarker of the individual response to aspirin enabling targeted antithrombotic therapy. METHODS: Blood samples were collected from 209 patients with intermittent claudication on daily aspirin therapy. Based on results from the arachidonic acid stimulated aggregation test, patients were defined as aspirin resistant (n = 92) or responders (n = 117)...
December 23, 2018: Clinical Biochemistry
Qian-Jie Tang, He-Ping Lei, Hong Wu, Ji-Yan Chen, Chun-Yu Deng, Wang-Sheng Sheng, Yong-Heng Fu, Xiao-Hong Li, Yu-Bi Lin, Ya-Ling Han, Shi-Long Zhong
MicroRNAs (miRNAs) are widely expressed in organisms and are implicated in the regulation of most biological functions. The present study investigated the association of plasma miRNAs with the clinical outcomes of dual antiplatelet therapy in coronary artery disease (CAD) patients who underwent percutaneous coronary intervention (PCI). Plasma miRNA levels were screened using high-throughput Illumina sequencing to evaluate the antiplatelet efficacy of clopidogrel and aspirin. Six plasma miRNAs (miR-126, miR-130a, miR-27a, miR-106a, miR-21, and miR-142) were associated with clopidogrel-treated platelet aggregation...
June 11, 2018: Acta Pharmacologica Sinica
Wei-Jan Chen, Ying-Hwa Chen, Yu-Juei Hsu, Kwang-Huei Lin, Yung-Hsin Yeh
BACKGROUND AND AIMS: Cilostazol, beyond its antiplatelet effect, is also capable of promoting vascular smooth muscle cell (VSMC) differentiation. The aim of this study was to explore the potential role of PTEN, known to associate with VSMC differentiation, and its related microRNA (miRNA) in cilostazol-dependent effects. METHODS AND RESULTS: Microarray analysis in balloon-injured rat carotid arteries comparing with and without balloon injury revealed that miR-132 was differentially expressed...
July 2018: Atherosclerosis
Li Peng, Jun Liu, Liuan Qin, Jia Liu, Shaozhi Xi, Caiyi Lu, Tong Yin
BACKGROUND: Both platelet-derived microRNAs and the genotype of CYP2C19*2 were implicated for the variability of clopidogrel antiplatelet responsiveness. However, their interaction on the antiplatelet responsiveness of clopidogrel in patients with acute coronary syndrome (ACS) remains unknown. METHODS: Consecutive clopidogrel-treated patients with ACS were recruited, with their antiplatelet responsiveness evaluated by the relative platelet inhibition (RI), as measured by light transmittance aggregometry (LTA) at baseline and 5days' after the maintenance treatment of clopidogrel...
September 2017: Thrombosis Research
Annarita Carino, Salvatore De Rosa, Sabato Sorrentino, Alberto Polimeni, Jolanda Sabatino, Gianluca Caiazzo, Daniele Torella, Carmen Spaccarotella, Annalisa Mongiardo, Antonio Strangio, Carol Filippis, Ciro Indolfi
Background. Circulating microRNAs are appealing biomarkers to monitor several processes underlying cardiovascular diseases. Platelets are a major source for circulating microRNAs. Interestingly, the levels of specific microRNAs were reported to correlate with the level of platelet activation. The aim of the present study was to test whether the treatment with the novel antiplatelet agent, ticagrelor, is associated with modulation in the levels of key platelet-derived microRNAs. Methods and Results. Patients were randomly selected from those participating in the SHIFT-OVER study, in which we had previously evaluated the effect of the therapeutic switch from clopidogrel to ticagrelor on platelet aggregation...
2016: BioMed Research International
Anne Zufferey, Mark Ibberson, Jean-Luc Reny, Séverine Nolli, Domitille Schvartz, Mylène Docquier, Ioannis Xenarios, Jean-Charles Sanchez, Pierre Fontana
Platelet reactivity (PR) is variable between individuals and modulates clinical outcome in cardiovascular (CV) patients treated with antiplatelet drugs. Although several data point to a genetic control of platelet reactivity, the genes contributing to the modulation of this phenotype are not clearly identified. Integration of data derived from high-throughput technologies may yield novel insights into the molecular mechanisms that govern platelet reactivity. The aim of this study is to identify candidate genes modulating platelet reactivity in aspirin-treated CV patients using an integrative network-based approach...
April 2016: Human Genetics
Dorothee Kaudewitz, Philipp Skroblin, Lukas H Bender, Temo Barwari, Peter Willeit, Raimund Pechlaner, Nicholas P Sunderland, Karin Willeit, Allison C Morton, Paul C Armstrong, Melissa V Chan, Ruifang Lu, Xiaoke Yin, Filipe Gracio, Katarzyna Dudek, Sarah R Langley, Anna Zampetaki, Emanuele de Rinaldis, Shu Ye, Timothy D Warner, Alka Saxena, Stefan Kiechl, Robert F Storey, Manuel Mayr
RATIONALE: Platelets shed microRNAs (miRNAs). Plasma miRNAs change on platelet inhibition. It is unclear whether plasma miRNA levels correlate with platelet function. OBJECTIVE: To link small RNAs to platelet reactivity. METHODS AND RESULTS: Next-generation sequencing of small RNAs in plasma revealed 2 peaks at 22 to 23 and 32 to 33 nucleotides corresponding to miRNAs and YRNAs, respectively. Among YRNAs, predominantly, fragments of RNY4 and RNY5 were detected...
February 5, 2016: Circulation Research
Dorothee Kaudewitz, Anna Zampetaki, Manuel Mayr
MicroRNA (miRNA, miR) measurements in patients with coronary heart disease are hampered by the confounding effects of medication commonly used in cardiovascular patients such as statins, antiplatelet drugs, and heparin administration. Statins reduce the circulating levels of liver-derived miR-122. Antiplatelet medication attenuates the release of platelet-derived miRNAs. Heparin inhibits the polymerase chain reactions, in particular the amplification of the exogenous Caenorhabditis elegans spike-in control, thereby resulting in an artefactual rise of endogenous miRNAs...
December 2015: Current Atherosclerosis Reports
Jota Mikami, Yukinori Kurokawa, Tsuyoshi Takahashi, Yasuhiro Miyazaki, Makoto Yamasaki, Hiroshi Miyata, Kiyokazu Nakajima, Shuji Takiguchi, Masaki Mori, Yuichiro Doki
BACKGROUND: The antitumor effects of antiplatelet agents in gastric cancer cells are not well known. In this study, the possibility of gastric cancer treatment with an antiplatelet agent, mainly aspirin, was examined both in vivo and in vitro. METHODS: For in vivo experiments, tumor-bearing mice were treated by an antiplatelet antibody or aspirin, and the tumor growth was compared. For in vitro experiments, human gastric cancer cell lines were used to confirm the cancer cell growth and inhibition by reducing the platelet count or using aspirin...
July 2016: Gastric Cancer
Rui Shi, Xin Zhou, Wen-Jie Ji, Ying-Ying Zhang, Yong-Qiang Ma, Jian-Qi Zhang, Yu-Ming Li
Platelets are anuclear cells and are devoid of genomic DNA, but they are capable of de novo protein synthesis from mRNA derived from their progenitor cells, megakaryocytes. There is mounting evidence that microRNA (miRNA) plays an important role in regulating gene expression in platelets. miR-223 is the most abundant miRNAs in megakaryocytes and platelets. One of the miR-223-regulated genes is ADP P2Y12, a key target for current antiplatelet drug therapy. Recent studies showed that a blunted response to P2Y12 antagonist, that is, high on-treatment platelet reactivity (HTPR), is a strong predictor of major cardiovascular events (MACEs) in coronary heart disease (CHD) patients receiving antiplatelet treatment...
2015: BioMed Research International
Mao Luo, Rong Li, Xin Deng, Meiping Ren, Ni Chen, Min Zeng, Kai Yan, Jiyi Xia, Fei Liu, Weizhong Ma, Yan Yang, Qin Wan, Jianbo Wu
AIMS: MicroRNA-103 (miR-103) plays a critical role in regulating glucose homeostasis in type 2 diabetes (DM2). Recent data suggest that secreted frizzled-related protein 4 (SFRP4) serves as a potential risk biomarker for prediabetic mellitus (pre-DM) and that platelets are enriched for miR-103. The objective of this study was to test the hypothesis that platelet-derived miR-103b (miR-103-as), which regulates SFRP4, might be a novel biomarker for the early diagnosis of DM2. METHODS: We evaluated platelet miR-103b expression in healthy subjects (n = 46), pre-DM subjects (n = 48), non-complicated diabetic subjects (n = 43) and diabetes mellitus type 2-coronary heart disease subjects (n = 36), respectively, and analyzed the relationship of these levels with its target gene SFRP4...
October 2015: Acta Diabetologica
Bernadeta Chyrchel, Justyna Totoń-Żurańska, Olga Kruszelnicka, Michał Chyrchel, Waldemar Mielecki, Maria Kołton-Wróż, Paweł Wołkow, Andrzej Surdacki
Decreased plasma levels of microRNA-223 (miR-223), predominantly of platelet origin, were proposed as a surrogate marker of efficacy of antiplatelet therapy. However, higher on-treatment platelet reactivity was associated with lower plasma miR-223 in patients with coronary artery disease (CAD) on dual antiplatelet therapy (DAPT) including clopidogrel and aspirin. Our aim was to compare plasma miR-223 and platelet reactivity in CAD patients on DAPT with newer P2Y12 antagonists vs. clopidogrel. We studied 21 men with CAD admitted to our centre owing to a non-ST-elevation acute coronary syndrome, and with an uncomplicated hospital course...
2015: Platelets
Deepak Voora, Geoffrey S Ginsburg, Axel Akerblom
No abstract text is available yet for this article.
January 2014: Future Cardiology
Xi-Yong Yu, Ji-Yan Chen, Zhi-Wei Zheng, Hong Wu, Li-Wen Li, Zhi-Wei Zhang, Zhi-Hong Chen, Qiu-Xiong Lin, Ya-Ling Han, Shi-Long Zhong
AIMS: Antiplatelet treatment can cause a change in plasma levels of platelet microRNAs (miRNAs). However, it is not clear whether the plasma level of platelet miRNAs can predict clinical outcomes of antiplatelet treatment. The present study aimed to evaluate the association of plasma miR-16, miR%E2%80%9121, miR-126, miR-26b, and miR-223 with the risk of clinical outcomes in dual antiplatelet-treated patients after percutaneous coronary intervention (PCI). METHODS AND RESULTS: A total of 491 Han Chinese patients who had received PCI and dual antiplatelet therapy were sequentially recruited to the study and followed for up to one year...
September 2013: EuroIntervention
Bertil Lindahl
Over the past two decades there have been dramatic changes in the diagnosis, treatment and prognosis of acute coronary syndrome (ACS). Several new treatment modalities have been added and the prognosis has improved dramatically. Biomarkers play a crucial role in the management of ACS. At present, cardiac troponin is the biomarker of choice for diagnosis of acute myocardial infarction (AMI). Currently, there are no other biomarkers, which can compete, neither regarding specificity nor regarding early sensitivity...
September 2013: Clinical Chemistry and Laboratory Medicine: CCLM
Peter Willeit, Anna Zampetaki, Katarzyna Dudek, Dorothee Kaudewitz, Alice King, Nicholas S Kirkby, Roxanne Crosby-Nwaobi, Marianna Prokopi, Ignat Drozdov, Sarah R Langley, Sobha Sivaprasad, Hugh S Markus, Jane A Mitchell, Timothy D Warner, Stefan Kiechl, Manuel Mayr
RATIONALE: MicroRNA (miRNA) biomarkers are attracting considerable interest. Effects of medication, however, have not been investigated thus far. OBJECTIVE: To analyze changes in plasma miRNAs in response to antiplatelet therapy. METHODS AND RESULTS: Profiling for 377 miRNAs was performed in platelets, platelet microparticles, platelet-rich plasma, platelet-poor plasma, and serum. Platelet-rich plasma showed markedly higher levels of miRNAs than serum and platelet-poor plasma...
February 15, 2013: Circulation Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"